



A service of the National Library of Medicine and the National Institutes of Health

My NCBI [Sign In] [Regi:

			4 " " " P	obmed.go.	<b>1.</b>				
All Databases	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Bor
Search PubMed		for					Pre	view Go	CI
	Limits	Preview/	Index <b>H</b> i	ر story Clip	board C	etails \			
	• Sea	rch History w	vill be lost	after eight	hours of in	activity.			

About Entrez NCBI Toolbar

**Text Version** 

- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

Entrez PubMed				
Overview				
Help   FAQ				
Tutorials				
New/Noteworthy				
E-Utilities				

PubMed Services Journals Database MeSH Database Single Citation Matcher **Batch Citation Matcher** Clinical Queries **Special Queries** LinkOut My NCBI

Related Resources Order Documents **NLM Mobile NLM Catalog NLM Gateway** TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Search	Most Recent Queries	Time	Result
#33	Search "transgenic mice" and "human antibody" and	10:31:28	<u>0</u>
	expression and Th2		
<u>#32</u>	Search #31 and Th2	10:30:46	<u>39</u>
<u>#31</u>	Search "transgenic mice" and "human and antibody"	10:30:08	<u>802</u>
	and expression		
	Search "transgenic mice" and "human and antibody"		<u>1753</u>
	Search "transgenic mice" and human and antibody	10:29:42	<u>1753</u>
	Search "transgenic mice"	10:29:22	
<u>#27</u>	Search human antibody expression and "transgenic	10:29:05	<u>802</u>
<b>"0.5</b>	mice"	10.05.40	70
	Search Bruggemann m	10:27:43	<u>72</u>
#24	Search "human monoclonal antibody" and mouse model	10:25:33	<u>40</u>
#23	Search "human monoclonal antibody" and mice	10:23:07	232
	Search "human monoclonal antibody" and transgenic		<u> 11</u>
	Search "monoclonal" and transgenic and Th2	10:21:08	63
	Search "monoclonal" and transgenic and Th2	09:51:38	<u>95</u> 1569
	Search "monoclonal Ab" and transgenic	09:51:21	3
		09:51:16	
	Search "monoclonal Ab" and transgene Search "monoclonal Ab" and transgene mice	09:51:09	<u>0</u>
		09:48:35	<u>0</u> <u>3</u>
	Search "monoclonal Ab" and "transgenic mice" Search "immunoglobulin and "transgenic mice"	09:46:14	<u>5</u> 27
	Search "immunoglobulin and transgenic mice"	09:40:14	4
	9	09:42:40	· Protessan Lanca
	Search immunoglobulin transgenic mice	09:41:29	-
<u># /</u>	Search human and immunoglobulin "transgenic mice" and	09:41:29	1418
#5	Search "human immunoglobulin" "transgenic mice"	09:37:56	<u>1</u>
11.20	and Th1		
#4	Search "human immunoglobulin" "transgenic mice"	09:37:39	<u>0</u>
	and Th2		
<u>#3</u>	Search "human immunoglobulin" "transgenic mice"	09:34:57	<u>67</u>

#2Search human immunoglobulin "transgenic mice"09:34:361418#1Search human immunoglobulin transgenic mice09:34:252271



Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Dec 14 2005 04:30:51

Set	Items	Description
S1	0	TRANSGENIC W MOUSE OR TRANSGENIC W MICE
S2	0	TRANSGENIC W MOUSE
S3	0	TRANSGENIC W MOUSE
S4	2093342	MOUSE
S5	313583	TRANSGEN?
S6	117	XENOMOUSE
S7	1	HUMAB-MOUSE
S8	7016	HUMAN (N) MONOCLONAL (N) ANTIBODY
S9	37596	TH1 AND TH2
S10	129888	S4 AND S5
S11	46	S10 AND S6
S12	9	S11 AND S8
S13	57	S10 AND S8
S14	0	S13 AND S9
S15	387089	MONOCLONAL (N) ANTIBODY
S16	2931	S10 AND S15
S17	79	S16 AND S9
S18	45	IL (W) 4 AND S17
S19	41	INTERLEUKIN (W) 4 AND S17
S20	37	RD S19 (unique items)
S21	38	RD S18 (unique items)
S22	0	C57BL/6 (N) ANTIBODY (N) PRODUCTION
S23	1066	C57BL/6
S24	42298	DS
S25	56427	ANTIBOD? (N) PRODUCTION
S26	7	S23 AND S25
S27	7	RD (unique items)
S28	35	S23 AND S15
S29	35	RD S28 (unique items)
S30	0	S9 AND "ANTIBOD? (N) SYNTHESIS
S31	5128	ANTIBODY (N) SYNTHESIS
S32	45	S31 AND S9
S33	25	RD (unique items)
?		

Welcome to STN International! Enter x:x

LOGINID: SSPTALAB1643

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
NEWS 1
                Web Page URLs for STN Seminar Schedule - N. America
     2
                "Ask CAS" for self-help around the clock
NEWS
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04
               CA/CAplus-Canadian Intellectual Property Office (CIPO) added
                to core patent offices
NEWS 6 OCT 13
                New CAS Information Use Policies Effective October 17, 2005
NEWS 7 OCT 17
                STN(R) AnaVist(TM), Version 1.01, allows the export/download
                of CAplus documents for use in third-party analysis and
                visualization tools
NEWS 8 OCT 27
                Free KWIC format extended in full-text databases
               DIOGENES content streamlined
NEWS 9 OCT 27
                EPFULL enhanced with additional content
NEWS 10 OCT 27
                CA/CAplus - Expanded coverage of German academic research
NEWS 11 NOV 14
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental
                spectral property data
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 14 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 15 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 16 DEC 14 CA/CAplus to be enhanced with updated IPC codes
NEWS 17 DEC 16 MARPATprev will be removed from STN on December 31, 2005
             DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
NEWS EXPRESS
              CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
              V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
              http://download.cas.org/express/v8.0-Discover/
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS INTER
              General Internet Information
             Welcome Banner and News Items
NEWS LOGIN
NEWS PHONE
             Direct Dial and Telecommunication Network Access to STN
NEWS WWW
             CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:29:24 ON 16 DEC 2005

COST IN U.S. DOLLARS SINCE FILE TOTAL

ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 12:29:37 ON 16 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Dec 9, 2005 (20051209/UP).

=> FIL HOME

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 0.06 0.27

FILE 'HOME' ENTERED AT 12:29:43 ON 16 DEC 2005

=> file biosis

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
0.63
0.90

FILE 'BIOSIS' ENTERED AT 12:31:32 ON 16 DEC 2005

Copyright (c) 2005 The Thomson Corporation

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 14 December 2005 (20051214/ED)

=> s transgen? (N) mouse

81150 TRANSGEN?

778180 MOUSE

L1 12904 TRANSGEN? (A) MOUSE

=> s Thl (p) Th2

14830 TH1

13605 TH2

L2 9034 TH1 (P) TH2

=> s monoclonal (w) antibod?

173749 MONOCLONAL

586543 ANTIBOD?

L3 152345 MONOCLONAL (W) ANTIBOD?

=> s antibod? (p) synthesis

586543 ANTIBOD?

549731 SYNTHESIS

L4 20783 ANTIBOD? (P) SYNTHESIS

=> s L1 and L2 and L3

L5 1 L1 AND L2 AND L3

=> d TI AB

L5 ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

TI Interaction within clusters of dendritic cells and helper T cells during initial Th1/Th2 commitment.

AB Cytokines are the main agents known to regulate Th1/Th2 commitment, where they may operate through paracrine activity within

clusters of T cells gathered around dendritic cells (DC). An in vitro system is used here to test this possibility, using clusters around DC composed of naive TCR-transgenic ovalbumin peptide 323-339-specific CD4+ T cells as targets plus TCR-transgenic pigeon cytochrome C peptide 88-104-specific CD4+ polarized Th1 or Th2 cells as inducers. The polarized inducer cells exerted their maximum effect when the two T cell populations were activated within the same cluster, implemented by allowing a single DC to present both their epitopes. finding thus supports the paracrine hypothesis. The system was then employed to explore the role of individual cytokines by means of inhibition by monoclonal antibodies. Development of Th2 commitment proved strictly dependent on the IL-4 produced by the Th2 inducers. For Th1 commitment, IFN-gamma and IL-12 were both needed, but with IFN-gamma required only during the initial period of culture. The rapid timing observed under these conditions places constraints on the molecular basis of commitment, and appears accurately to reflect the physiological response in vivo.

=> s L1 and L3 L6 188 L1 AND L3 => s L6 and L4 L7 6 L6 AND L4

=> d TI AB

L7 ANSWER 1 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN SV40-derived ribozyme construct mediates effective destruction of human alphal-antitrypsin transcripts in a transgenic mouse model.

Background: Human alphal-antitrypsin (alphal-AT) deficiency is a genetic AB disorder that leads to emphysema and chronic liver disease. The lung disease is thought to reflect insufficient normal alphal-AT activity in the circulation, whereas the liver disease occurs because abnormal alphal-AT accumulates in hepatocytes. The bi-functional liver-directed approach we are using involves inhibiting abnormal alphal-AT protein production employing a gene-specific ribozyme, and the synthesis of a ribozyme-resistant wild-type protein by engineering a modified alphal-AT cDNA. Our previous findings showed that the modified human alphal-AT cDNA delivered by the SV40 vector led to acceptable levels of the human protein in mice for one year. In the present study, we evaluated the efficacy of ribozyme-mediated destruction of targeted human PiZ transcripts in vivo. Methods: Transgenic mice carrying the human alphal-AT PiZ allele were infected via an indwelling catheter in the portal vein with recombinant SV40 virus containing a ribozyme designed to target human alphal-AT mRNA. The destruction of PiZ transcripts in ribozyme-treated transgenic mice was evaluated by real time quantitative RT-PCR, and human alphal-AT in mouse serum was quantified by ELISA, using a specific monoclonal antibody against human alpha1-AT. Results: Quantitative RT-PCR analysis revealed that the average reduction of human PiZ transcripts in the mouse livers was 57.1+-18.3% (p=0.05) in four mice that were sacrificed between 6 to 16 weeks after transduction with the ribozyme construct. No change in mouse albumin mRNA was found. The administration of the ribozyme lowered serum levels of human alpha1-AT to 42.4+-12.1% of pretreatment values (p<0.01) 3-25 weeks post-transduction in six mice, whereas serum human alphal-AT levels in transgenic mice not treated with the ribozyme were unchanged. Serum human alphal-AT in one mouse was reduced by 99% at 6 weeks, and human alphal-AT PiZ transcripts were undetectable by quantitative RT-PCR from the liver of that mouse. Moreover, quantitative RT-PCR showed that the levels of mouse alphal-AT, albumin, and beta-actin mRNA from that mouse remained the same as in control mice despite the essentially complete loss of the human alphal-AT transcripts. Conclusion: Findings in the present study demonstrated that an SV40-derived construct containing a ribozyme is highly effective in lowering human alphal-AT mRNA and protein levels in vivo. When considered together, the results of the present study and our previous reports suggest that our recombinant SV40 virus system represents the first step in the development of a clinically valuable gene therapy approach for alphal-AT deficiency.

## => d L7 TI 1-6

- L7 ANSWER 1 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN SV40-derived ribozyme construct mediates effective destruction of human alphal-antitrypsin transcripts in a **transgenic mouse** model.
- L7 ANSWER 2 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN Cellular interactions with a cryptic element within collagen type-I promotes B16 melanoma tumor growth in vitro and in vivo.
- L7 ANSWER 3 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN TI Human antibodies by design.
- L7 ANSWER 4 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN TI Anti-idiotype monoclonal antibodies specific for the MOPC167 anti-phosphocholine transgene-encoded antibody.
- L7 ANSWER 5 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN TI Fetal hemoglobin induction by acetate, a product of butyrate catabolism.
- L7 ANSWER 6 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN TI TISSUE-SPECIFIC EXPRESSION OF THE HUMAN RENIN GENE IN TRANSGENIC MICE.

=> File Medline embase caplus scisearch COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 23.75 24.65

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 12:45:27 ON 16 DEC 2005

FILE 'EMBASE' ENTERED AT 12:45:27 ON 16 DEC 2005 Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 12:45:27 ON 16 DEC 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 12:45:27 ON 16 DEC 2005 Copyright (c) 2005 The Thomson Corporation

=> s L1 and L3

L8 1305 L1 AND L3

=> s L8 and L2

L9 27 L8 AND L2

=> duplicate remove
ENTER L# LIST OR (END):L9
DUPLICATE PREFERENCE IS 'EMBASE, CAPLUS, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):Y
ENTER FILE NAMES OF DUPLICATES TO KEEP:n
'N' IS NOT VALID. VALID FILE NAMES ARE 'EMBASE, CAPLUS, SCISEARCH'
You have entered a file name of duplicates to keep that is not

referenced by any of the L#s specified for this DUPLICATE command. The file names of duplicates that can be kept are listed above. Please enter one of these file names. ENTER FILE NAMES OF DUPLICATES TO KEEP: ENTER FILE NAMES OF DUPLICATES TO KEEP: ENTER FILE NAMES OF DUPLICATES TO KEEP:L9 'L17' IS NOT VALID. VALID FILE NAMES ARE 'EMBASE, CAPLUS, SCISEARCH' You have entered a file name of duplicates to keep that is not referenced by any of the L#s specified for this DUPLICATE command. The file names of duplicates that can be kept are listed above. Please enter one of these file names. ENTER FILE NAMES OF DUPLICATES TO KEEP:s L( 'S' IS NOT VALID. VALID FILE NAMES ARE 'EMBASE, CAPLUS, SCISEARCH' You have entered a file name of duplicates to keep that is not referenced by any of the L#s specified for this DUPLICATE command. The file names of duplicates that can be kept are listed above. Please enter one of these file names. ENTER FILE NAMES OF DUPLICATES TO KEEP:log Y 'LOG' IS NOT VALID. VALID FILE NAMES ARE 'EMBASE, CAPLUS, SCISEARCH' You have entered a file name of duplicates to keep that is not referenced by any of the L#s specified for this DUPLICATE command. The file names of duplicates that can be kept are listed above. Please enter one of these file names.

## Freeform Search

Database:	US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins				
Term:	L8 and "antibody synthesis"				
Display:	10 Documents in <u>Display Format</u> : - Starting with Number 1	Ī			
Generate:	: O Hit List O Hit Count O Side by Side O Image				
Search					
Search History					

DATE: Friday, December 16, 2005 Printable Copy Create Case

Set Name ide by side	Query	Hit Count	Set Name result set	
DB=PGPB, USPT, USOC, EPAB, JPAB, DWPI; PLUR=YES; OP=ADJ				
<u>L12</u>	L11 and "anti IL-12 antibody"	0	<u>L12</u>	
<u>L11</u>	L8 and IL-4	775	<u>L11</u>	
<u>L10</u>	L8 and "antibody synthesis"	14	<u>L10</u>	
<u>L9</u>	L8 and "antibody adj synthesis"	0	<u>L9</u>	
<u>L.8</u>	L7 and "antibody production"	867	<u>L8</u>	
<u>L7</u>	L6 and Th1	1310	<u>L7</u>	
<u>L6</u>	L3 and Th2	1416	<u>L6</u>	
<u>L5</u>	L3 and Th2	1416	<u>L5</u>	
<u>L4</u>	"monoclonal adj antibody"	0	<u>L4</u>	
<u>L3</u>	L1 and "monoclonal antibody"	12568	<u>L3</u>	
<u>L2</u>	L1 and "human and antibody and expression"	0	<u>L2</u>	
<u>L1</u>	"transgenic mouse"	17819	<u>L1</u>	

**END OF SEARCH HISTORY**